{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:46:40Z","timestamp":1782996400176,"version":"3.54.5"},"reference-count":43,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"unspecified","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Department of Defense Early Career Investigator grant","award":["KCRP AKCI-ECI"],"award-info":[{"award-number":["KCRP AKCI-ECI"]}]},{"name":"Department of Defense Early Career Investigator grant","award":["W81XWH-20-1-0882"],"award-info":[{"award-number":["W81XWH-20-1-0882"]}]},{"name":"NIH\/NCI","award":["1R37CA279822-01"],"award-info":[{"award-number":["1R37CA279822-01"]}]},{"name":"NIH\/NCI","award":["P30CA016359"],"award-info":[{"award-number":["P30CA016359"]}]},{"name":"Kidney Cancer Association (KCA) Trailblazer Award","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Louis Goodman and Alfred Gilman Yale Scholar Fund","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100010900","name":"Yale Cancer Center","doi-asserted-by":"crossref","award":["P30CA016359"],"award-info":[{"award-number":["P30CA016359"]}],"id":[{"id":"10.13039\/100010900","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["bmjonc"],"accepted":{"date-parts":[[2026,6,8]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have demonstrated durable clinical benefit in a subset of patients with metastatic renal cell carcinoma (RCC), yet the molecular features that govern therapeutic response within the primary tumour remain poorly defined. This is of particular importance in the current era, where cytoreductive nephrectomy is less commonly performed and many patients with metastatic disease still have the primary RCC tumour in place. To deepen our understanding of ICI response in the primary tumour and to understand the evolution of RCC on ICI, we conducted a comprehensive genomic analysis of paired pretreatment and post-treatment primary RCC tumours treated with ICI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting and participants<\/jats:title>\n                    <jats:p>We performed a multimodal analysis of 46 ICI-treated primary RCC tumour specimens from 33 patients, including 13 matched pretreatment biopsies and post-treatment nephrectomies to investigate the genomic and transcriptomic evolution of tumours exposed to ICI therapy. Seventeen samples were from responders (&gt;30% radiographic shrinkage, n=4 pretreatment, n=13 post-treatment) and 29 samples were from non-responders (&lt;30% shrinkage, n=11 pretreatment, n=18 post-treatment). Whole-exome and RNA-seq were performed at Caris Life Sciences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this limited cohort, pretreatment responder biopsies are enriched for immune-related gene programmes, including B cell and tertiary lymphoid structure signatures. Longitudinal analysis reveals immune pathways decline in responders while non-responders show signatures of T cell exhaustion. However, the small number of patients with paired samples constrains statistical power and limits generalisability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings highlight the value of primary tumour profiling in understanding ICI response dynamics in RCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjonc-2025-001031","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:10:31Z","timestamp":1782994231000},"page":"e001031","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Investigating the determinants of immunotherapy response in the primary tumour of clear cell renal cell carcinoma (RCC)"],"prefix":"10.1136","volume":"5","author":[{"given":"Cerise","family":"Tang","sequence":"first","affiliation":[{"name":"Yale Center of Cellular and Molecular Oncology, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Poduval","sequence":"additional","affiliation":[{"name":"Yale Center of Cellular and Molecular Oncology, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanna","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, University of California San Diego Department of Medicine, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Panian","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, University of California San Diego Department of Medicine, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava","family":"Saidian","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Tennessee Health Science Center, Memphis, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishabh","family":"Rout","sequence":"additional","affiliation":[{"name":"Yale Center of Cellular and Molecular Oncology, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"van Dijk","sequence":"additional","affiliation":[{"name":"Yale Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana R","family":"McKay","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, University of California San Diego Department of Medicine, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4543-5553","authenticated-orcid":false,"given":"David A","family":"Braun","sequence":"additional","affiliation":[{"name":"Yale Center of Cellular and Molecular Oncology, Yale School of Medicine, New Haven, Connecticut, USA"},{"name":"Yale Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"2026070205101856000_5.2.e001031.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026982"},{"key":"2026070205101856000_5.2.e001031.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"2026070205101856000_5.2.e001031.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"key":"2026070205101856000_5.2.e001031.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665"},{"key":"2026070205101856000_5.2.e001031.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.10.001"},{"key":"2026070205101856000_5.2.e001031.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-020-0282-3"},{"key":"2026070205101856000_5.2.e001031.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035716"},{"key":"2026070205101856000_5.2.e001031.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0053-3"},{"key":"2026070205101856000_5.2.e001031.9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamaoncol.2021.5981","article-title":"Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma","volume":"8","author":"Motzer","year":"2022","journal-title":"JAMA Oncol"},{"key":"2026070205101856000_5.2.e001031.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1044-8"},{"key":"2026070205101856000_5.2.e001031.11","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s43018-024-00896-w","article-title":"Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma","volume":"6","author":"Jammihal","year":"2025","journal-title":"Nat Cancer"},{"key":"2026070205101856000_5.2.e001031.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.03.002"},{"key":"2026070205101856000_5.2.e001031.13","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0991"},{"key":"2026070205101856000_5.2.e001031.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0839-y"},{"key":"2026070205101856000_5.2.e001031.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30436-8"},{"key":"2026070205101856000_5.2.e001031.16","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bts635"},{"key":"2026070205101856000_5.2.e001031.17","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.4197"},{"key":"2026070205101856000_5.2.e001031.18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004873","article-title":"CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing","volume":"12","author":"Talevich","year":"2016","journal-title":"PLoS Comput Biol"},{"key":"2026070205101856000_5.2.e001031.19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30445-9"},{"key":"2026070205101856000_5.2.e001031.20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000147","article-title":"Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project","volume":"8","author":"Merino","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026070205101856000_5.2.e001031.21","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btu548"},{"key":"2026070205101856000_5.2.e001031.22","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8"},{"key":"2026070205101856000_5.2.e001031.23","doi-asserted-by":"crossref","unstructured":"Korotkevich G , Sukhov V , Budin N , et al . Fast gene set enrichment analysis. Bioinformatics [Preprint] 2016. doi:10.1101\/060012","DOI":"10.1101\/060012"},{"key":"2026070205101856000_5.2.e001031.24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"2026070205101856000_5.2.e001031.25","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btaa223"},{"key":"2026070205101856000_5.2.e001031.26","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1995.tb02031.x)"},{"key":"2026070205101856000_5.2.e001031.27","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-018-0605-7","article-title":"Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine","volume":"10","author":"Conway","year":"2018","journal-title":"Genome Med"},{"key":"2026070205101856000_5.2.e001031.28","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0386"},{"key":"2026070205101856000_5.2.e001031.29","doi-asserted-by":"publisher","DOI":"10.1038\/nature08460"},{"key":"2026070205101856000_5.2.e001031.30","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"2026070205101856000_5.2.e001031.31","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0639-4"},{"key":"2026070205101856000_5.2.e001031.32","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao4572"},{"key":"2026070205101856000_5.2.e001031.33","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.3.1719"},{"key":"2026070205101856000_5.2.e001031.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.10.003"},{"key":"2026070205101856000_5.2.e001031.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.02.001"},{"key":"2026070205101856000_5.2.e001031.36","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006667","article-title":"Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma","volume":"11","author":"Xu","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026070205101856000_5.2.e001031.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1914-8"},{"key":"2026070205101856000_5.2.e001031.38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0923"},{"key":"2026070205101856000_5.2.e001031.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.02.013"},{"key":"2026070205101856000_5.2.e001031.40","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124989","article-title":"Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma","volume":"4","author":"Najjar","year":"2019","journal-title":"JCI Insight"},{"key":"2026070205101856000_5.2.e001031.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2021.02.015"},{"key":"2026070205101856000_5.2.e001031.42","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01229-8"},{"key":"2026070205101856000_5.2.e001031.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.02.015"}],"container-title":["BMJ Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjonc-2025-001031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:10:40Z","timestamp":1782994240000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjoncology.bmj.com\/lookup\/doi\/10.1136\/bmjonc-2025-001031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,7,2]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjonc-2025-001031"],"URL":"https:\/\/doi.org\/10.1136\/bmjonc-2025-001031","relation":{},"ISSN":["2752-7948"],"issn-type":[{"value":"2752-7948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}